This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Safety and tolerability of galantamine in possible Alzheimer’s disease with or without cerebrovascular disease and vascular dementia in Thai patients


Senanarong, Vorapun, Poungvarin, Niphon, Phanthumchinda, Kammant, Thavichachart, Nuntika, Chankrachang, Siwaporn, Praditsuwan, Rungnirund, Nidhinandana, Samart


Journal Of The Medical Association Of Thailand = Chotmaihet Thangphaet, Volume: 92 Suppl 2, Pages.: S12-S18

Year of Publication



The purpose of this study was to explore factors that influence the clinical safety and tolerability associated with galantamine administration in Thai Alzheimer’s disease patients with or without cerebrovascular disease and vascular dementia. This was an analysis of previous study. Tolerability and safety profile were analyzed according to sex, age, body weight, Thai mental state examination (TMSE) score, Alzheimer’s disease assessment scale-cognitive subscale (ADAS-cog) score, and Alzheimer’s disease cooperative study/activities of daily living (ADCS/ADL) score. The most common adverse events were nausea, dizziness, and weight loss which more often occurred during the dose-escalation phase. Mean body weight lost at week 24 was 0.9 kg. Sex, age, body weight, and ADAS-cog score did not influence the incidence of any adverse events. Dizziness was more likely to occur in patients with low TMSE and high ADCS/ADL score (p = 0.02 and p = 0.050, respectively). Patients with TMSE score equal or higher than 23 more often experienced muscle cramps and fatigue than who had TMSE lower 23 (p < 0.05). However, flexible dose escalation of galantamine with a 4-week schedule was safe and well tolerated in Thai AD patients.;


adverse effects, aged, aged, 80 and over, alzheimer disease, and, cerebrovascular disorders, cholinesterase inhibitors, cohort studies, complications, drug, drug therapy, female, galantamine, humans, male, middle aged, psychology, safety, thailand, therapeutic use, tolerability

Countries of Study


Types of Dementia

Vascular Dementia

Type of Outcomes

ADLs/IADLs, Cognition, Other, Physical Health

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime